https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-paraganglioma-glomus-jugulare-tumor-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-304651&utm_campaign=recommended-articles-pi
Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Paraganglioma (Glomus Jugulare Tumor).
hoffmann la rocheglomus jugulareatezolizumabparaganglioma